Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy

https://doi.org/10.1016/0002-9343(93)90259-RGet rights and content

Abstract

purpose: An increased risk of high-grade non-Hodgkin's lymphoma is observed in patients who are seropositive for human immunodeficiency virus (HIV). Treatment of such patients is complicated by their underlying acquired immunodeficiency syndrome (AIDS). Intensive strategies such as those used in non-HIV-related lymphoma may be poorly tolerated. However, patients without severe AIDS may derive significant benefits from such an approach. In a prospective multicenter study, treatment outcomes were assessed in 141 cases of HIV-seropositive lymphomas submitted to aggressive chemotherapy.

patients and methods: Adult patients with lymphoma with a performance status less than 3 and no active opportunistic infection were consecutively treated with three cycles of doxorubicin 75 mg/m2, cyclophosphamide 1,200 mg/m2, vindesine 2 mg/m2 for 2 days, bleomycin 10 mg for 2 days, and prednisolone 60 mg/m2 for 5 days (ACVB). This treatment was followed by a consolidation phase of high-dose methotrexate plus leucovorin, ifosfamide, etoposide, asparaginase, and cytarabine (LNH84). Central nervous system prophylaxis with intrathecal methotrexate was routinely used. Zidovudine maintenance therapy was started after chemotherapy. Ninety-three patients had high-grade lymphomas (59 Burkitt's type) and 48 had intermediate-grade lymphomas. Disseminated stage III-IV was present in 86 patients, meningeal involvement in 29, and bone marrow infiltration in 30; 62 patients had more than 2 extranodal localizations. Lactate dehydrogenase levels were above the normal value in 95 cases. The median CD4-positive lymphocyte count was 227 X 106/L.

results: Eighty-nine patients (63%) achieved complete remission (CR) and 19 (13%) partial remission, whereas 13 did not respond and 20 (14%) died during the course of ACVB, 8 of them from progressive disease. With a median follow-up of 28 months, median survival and disease-free survival were 9 and 16 months, respectively. Median survival for nonresponders was 5 months; 23 patients died of opportunistic infections while in persistent CR. In multivariate analysis, four factors were strongly associated with shorter survival: (1) CD4 count less than 100 × 106/L, (2) performance status greater than 1, (3) immunoblastic lymphoma, and (4) prior AIDS. In the absence of all risk factors, the probability of survival at 2 years was 50%.

conclusion: In a selected group of HIV-related lymphomas, intensive chemotherapy with LNH84 is feasible and yields a high CR rate. Survival is short due to death from HIV-related infections; however, in a subgroup of patients without adverse prognostic factors, long-term remission was observed.

References (21)

  • MA Bermudez et al.

    Non-Hodgkin's lymphoma in a population with or at risk for acquired immunodeficiency syndrome: indications for intensive chemotherapy

    Am J Med

    (1989)
  • V Beral et al.

    AIDS-associated non-Hodgkin lymphoma

    Lancet

    (1991)
  • JL Ziegler et al.

    Non-Hodgkin's lymphomas in 90 homosexual men

    N Engl J Med

    (1984)
  • MH Gail et al.

    Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome

    J Natl Cancer Inst

    (1991)
  • LD Kaplan et al.

    AIDS-associated non-Hodgkin's lymphoma in San Francisco

    JAMA

    (1989)
  • AM Levine et al.

    Human immunodeficiency virus-related lymphoma

  • AM Levine et al.

    Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma

  • PS Gill et al.

    AIDS-related malignant lymphoma: results of prospective treatment trials

    J Clin Oncol

    (1987)
  • M Raphael et al.

    Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome

    Arch Pathol Lab Med

    (1991)
  • JO Armitage et al.

    Interpretation of clinical trials in diffuse large-cell lymphoma

    J Clin Oncol

    (1988)
There are more references available in the full text version of this article.

Cited by (135)

  • TRIM11 promotes lymphomas by activating the β-catenin signaling and Axin1 ubiquitination degradation

    2020, Experimental Cell Research
    Citation Excerpt :

    According to tumor cells, lymphoma can be divided into non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) [1], and according to different lymphocyte sources, lymphoma can also be divided into B cell, T cell and natural killer (NK) cell lymphoma Immunologic characterization of human malignant lymphomas [2–4]. At present, lymphoma is mainly treated by radiation, chemical drugs, bone marrow transplantation and surgery [5–8]. However, due to the high degree of heterogeneity of lymphoma, lymphomas of different pathological types and stages are highly different in terms of treatment intensity and prognosis.

  • Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: A prospective study

    2007, Blood
    Citation Excerpt :

    Patients with good performance status (ECOG ≤ 2) had a good outcome as 70% were alive at 2 years. As expected in ARL,30,35,36 a CD4 cell count lower than 200 × 106/L was associated with poor outcome. Combining these 2 factors, we provide a prognosis index to define a patient subset with a clear benefit in survival when treated with LMB regimen.

  • AIDS-related non-Hodgkin lymphoma: Final analysis of 485 patients treated with risk-adapted intensive chemotherapy

    2006, Blood
    Citation Excerpt :

    Patients received CHOP-based chemotherapy after a pretreatment stratification of dose intensity according to their HIV score. This score was defined by the results of multivariate regression analysis in our previous trials.14,30 It is based on 3 independent risk factors (Eastern Cooperative Oncology Group [ECOG] performance status of 2 to 4, prior AIDS, and a CD4+ cell count below 0.10 × 109/L [100/mm3]) and leads to patient classification according to 3 degrees of risk: good (HIV score, 0 factors), intermediate (HIV score, 1 factor), and poor (HIV score, 2 to 3 factors).

View all citing articles on Scopus

This work was supported by ANRS (Agence Nationale de Recherche sur le SIDA), Paris, France, ANLAIDS (Associazione Italiana Lotta contro l'AIDS), Roma, Italy, and GELA (Groupe d'Etude des Lymphomes de l'Adulte), Paris, France.

View full text